Opinion

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Photo from Lernik Ohanjanian/LinkedIn

Apr 30, 2024, 16:02

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Lernik Ohanjanian, Senior Medical Director at Miltenyi Biomedicine, shared on LinkedIn:

“We are standing on the cusp of revolution in drug discovery and development, with artificial intelligence (AI) emerging as a transformative tool to improve cancer patient outcomes.

Let’s use AI responsibly in target identification and validation, acceleration of clinical trials, personalization of treatments, enhancing drug formulations, streamlining regulatory approvals and above all improving patient outcomes.”

No alt text provided for this image

Source: Lernik Ohanjanian/LinkedIn

AI in healthcare AI in oncology cancer drug development drug discovery improving patient outcomes Lernik Ohanjanian Miltenyi Biomedicine OncoDaily Oncology

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage